GLP1 (IHC-grade), Glucagon-Like Peptide 1 Receptor Antibody

NEW

GLP1 (IHC-grade), Glucagon-Like Peptide 1 Receptor Antibody

£ 335.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

Order number: 7TM0249N-IC
Content: 100 µl
Host: Rabbit

The GLP1 receptor antibody is directed against the distal end of the carboxyl-terminal tail... more

Close menu

The GLP1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GLP1 Receptor. It can be used to detect total GHRH receptors in Western blots independent of phosphorylation. The GLP1 antibody can also be used to isolate and enrich GLP1 receptors from cell and tissue lysates. It also detects GLP1 in formalin-fixed, paraffin-embedded tissue sections by immunohistochemistry.

Available downloads:

Alternative Names GHRHR, Growth Hormone Releasing Hormone Receptor... more

Close menu

Alternative Names	GHRHR, Growth Hormone Releasing Hormone Receptor
IUPHAR Target ID	247
UniProt ID	Q02643
Western Blot (WB)	1:1000
Immunohistochemistry (IHC)	1:100
Species Reactivity	Human
Host / Isotype	Rabbit / IgG
Class	Polyclonal
Immunogen	A synthetic peptide presents distal end of carboxyl-terminal tail of human GHRHR
Form	Liquid
Purification	Antigen affinity chromatography
Storage buffer	Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions	short-term 4°C, long-term -20°C

Figure 1. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in... more

Close menu

Figure 1. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in breast carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (7TM0247N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, GHRH receptors were uniformly detected at the plasma membrane in breast carcinoma.

Figure 2. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in ovarian carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (77TM0247N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, GHRH receptors were detected predominantly at the level of plasma membrane in ovarian carcinoma.

Figure 3. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in prostate carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (77TM0247N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, GHRH receptors were detected predominantly at the level of plasma membrane in prostate carcinoma.

Figure 4. Validation of the Growth Hormone-Releasing Hormone Receptor in pituitary adenoma. Growth hormone-producing pituitary adenoma was homogenated and immunoblotted using anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (7TM0247N-IC) at a dilution of 1:1000 in presence (+) or absence (-) of 10 µg/ml peptide antigen. Note, absence of peptide leads to detection of GHRH receptors in pituitary adenoma but not in presence of peptide.